Relative lung deposition of tobramycin from a MicroAir nebuliser

M. Mashat, B. J. Clark, K. H. Assi, H. Chrystyn (Bradford, United Kingdom)

Source: Annual Congress 2006 - Pathophysiology of lung disease
Session: Pathophysiology of lung disease
Session type: Thematic Poster Session
Number: 3871
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Mashat, B. J. Clark, K. H. Assi, H. Chrystyn (Bradford, United Kingdom). Relative lung deposition of tobramycin from a MicroAir nebuliser. Eur Respir J 2006; 28: Suppl. 50, 3871

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacokinetics of tobramycin nebulizer solution (300mg/4ml) administered by Pari e-Flow rapid vs Pari LC plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection
Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis
Year: 2012


The effect of nebulizer systems in inhaled tobramycin
Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more
Year: 2010


In-vitro nebulised dose emission characteristics of a tobramycin solution (75mg/ml) using an I-Neb (I-NEB) and a pari LC+ driven by a TurboBoy compressor (PARI) nebuliser
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011


In-vitro comparison of tobramycin nebulised using two different nebuliser systems
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I
Year: 2010


In vitro comparison of Pulmicort Respules™ with Clenil® pro aerosol in combination with three nebulisers
Source: Eur Respir J 2002; 20: Suppl. 38, 41s
Year: 2002

Intrapulmonary pharmacokinetics of laninamivir in healthy subjects: Comparison between a nebulizer and a dry powder inhaler
Source: International Congress 2018 – New therapies for respiratory infections: experimental and translational studies
Year: 2018




Assessment of lung deposition and pharmacokinetics in 12 lung transplanted patients after inhalation of a novel liposomal ciclosporin a (CsA) formulation by the eFlow electronic nebuliser
Source: Eur Respir J 2007; 30: Suppl. 51, 29s
Year: 2007

Effect of I:E ratio on delivery of colistimethate sodium from breath-enhanced and breath-activated nebulizers
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013


Similar delivery of ipratropium bromide is possible at approximately one-half dose via a breath-actuated nebulizer compared with a continuous nebulizer
Source: Eur Respir J 2005; 26: Suppl. 49, 306s
Year: 2005

Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Assessment on the efficiency of Clenny Aerosol, a new jet nebulizer with breath-enhanced bulb
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001

In vitro evaluation of spacers in comparison with T-adapters in mechanical ventilation with pressurized metered dose inhalers (pMDI) and vibrating mesh nebulizer.
Source: International Congress 2019 – COPD and other specific entities in intensive care unit medicine
Year: 2019

Lung deposition of an aerosol produced by a new inhalation device for ventilated patients
Source: Eur Respir J 2005; 26: Suppl. 49, 88s
Year: 2005

A breath-actuated nebulizer provides greatly reduced fugitive aerosol emissions compared with a continuously operating nebulizer
Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology II
Year: 2007


Aerosol characteristics of a unique breath-actuated nebulizer
Source: International Congress 2017 – Lung function practice in daily life
Year: 2017


Lung deposition of two bronchodilators in subjects with (COPD) when administered via standard jet nebulizer or Handihaler® using functional respiratory imaging (FRI).
Source: Virtual Congress 2020 – Inhaler devices in COPD: technical advances, adherence studies and more
Year: 2020


Particle size and gravimetric characteristics of Clenny Aerosol, a new jet nebulizer with breath enhanced bulb
Source: Eur Respir J 2001; 18: Suppl. 33, 99s
Year: 2001

In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014

Efficiency of ipratropium bromide and salbutamol deposition in the lung delivered via a soft-spray inhaler or chlorofluorocarbon metered-dose inhaler
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011


Successful conversion of patients using nebulised iloprost from multisonic nebuliser to adaptive aerosol delivery nebuliser
Source: Eur Respir J 2007; 30: Suppl. 51, 345s
Year: 2007